Conceptually, at least, the simultaneous binding of gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER 2/neu] at two different endogenous trophic receptors on the same cancer cell type offers the probability of evoking a greater degree of selectively “targeted” anti-neoplastic cytotoxicity compared to the selective binding of just a single covalent gemcitabine immunochemotherapeutic. The gene discussed is EGFR; the disease is cancer.